Internal Medicine, Rheumatology · Margate, FL
NPI
1659508166
Since 2009
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
4
Medicare group memberships
Hospitals
3
Hospital affiliations
5901 Colonial Dr Ste 303
Margate, FL, 33063
Phone (954) 281-8891
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
134,126 services
Medicare patients, 2024
348
Average age 75
Drug cost, 2024
$3.0M
2,490 prescriptions
Company payments, 2025
$215K
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jigar Shah was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 39,600 times for 16 patients. In total Jigar Shah billed 134,126 services in 58 codes, and Medicare paid $2.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 39,600 | 16 | $3.62 | $143K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 38,010 | 31 | $8.54 | $324K |
| J3262 Injection, tocilizumab, 1 mg | Office | 24,532 | 12 | $3.97 | $98K |
| J0897 Injection, denosumab, 1 mg | Office | 6,720 | 75 | $20.47 | $138K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,771 | 12 | $0.23 | $403 |
| 96401 Chemotherapy Administration | Office | 690 | 113 | $60.14 | $41K |
| 99214 Office E&M - Established | Office | 545 | 242 | $106.22 | $58K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 421 | 227 | $13.77 | $5,797 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 406 | 49 | $0.09 | $34.52 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 394 | 43 | $0.77 | $303 |
| 96413 Chemotherapy Administration | Office | 319 | 46 | $108.62 | $35K |
| 99213 Office E&M - Established | Office | 218 | 149 | $73.74 | $16K |
| 96415 Chemotherapy Administration | Office | 173 | 14 | $23.77 | $4,112 |
| 99204 Office E&M - New | Office | 102 | 102 | $136.19 | $14K |
| 96375 Injection Administration | Office | 80 | 14 | $13.00 | $1,040 |
By year: 2022 $1.2M for 92,942 services; 2023 $1.3M for 105,033 services; 2024 $2.0M for 134,126 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jigar Shah prescribed most often to Medicare patients was Prednisone, with 280 prescriptions and refills. In total Jigar Shah wrote 2,490 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 280 | 337 | 115 | $1,295 |
| Hydroxychloroquine Sulfate Generic | 234 | 504 | 92 | $6,800 |
| Tramadol Hcl Generic | 160 | 160 | 52 | $715 |
| Methotrexate Methotrexate Sodium | 157 | 425 | 83 | $3,801 |
| Meloxicam Generic | 140 | 230 | 76 | $448 |
| Gabapentin Generic | 132 | 308 | 54 | $1,704 |
| Alendronate Sodium Generic | 119 | 279 | 43 | $567 |
| Allopurinol Generic | 72 | 136 | 27 | $434 |
| Humira(Cf) Pen Adalimumab | 61 | 61 | Under 11 | $428K |
| Celecoxib Generic | 60 | 92 | 31 | $3,558 |
| Methylprednisolone Generic | 53 | 53 | 45 | $285 |
| Tymlos Abaloparatide | 50 | 50 | Under 11 | $140K |
| Acetaminophen-Codeine Acetaminophen With Codeine | 49 | 49 | 14 | $590 |
| Mycophenolate Mofetil Generic | 46 | 90 | 17 | $4,239 |
| Rinvoq Upadacitinib | 46 | 46 | Under 11 | $298K |
Brand drugs: 506 claims; generic drugs: 1,984 claims; opioid claims: 220.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jigar Shah $215K ($215K in general payments such as food, travel and fees) from 26 companies. The largest payer was Amgen Inc. with $96K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 123 | $96K |
| UCB, Inc. UCB.BR | 34 | $25K |
| Abbvie Inc. ABBV | 45 | $25K |
| Aurinia Pharma U.S., Inc. AUPH | 44 | $24K |
| AstraZeneca Pharmaceuticals LP AZN | 28 | $22K |
| GlaxoSmithKline, LLC. GSK | 20 | $17K |
| Sobi, Inc SOBI.ST | 6 | $3,026 |
| AstraZeneca UK Limited AZN | 6 | $757 |
| Janssen Biotech, Inc. JNJ | 2 | $200 |
| ANI Pharmaceuticals, Inc. ANIP | 10 | $175 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.